Due to the COVID-19 pandemic, the 2020 Answering TTP research grant competition deadline has been extended at least two months, until June 1, 2020. As the situation continues to evolve we will consider further extensions. Take care.
Answering TTP Foundation is excited to learn that Health Canada has approved the use of caplacizumab in combination with plasma exchange and immunosuppression for the treatment of aTTP in adults.
The first Virtual Peer Support session was held on Jan 16, 2020 and was a success! We had a total of eight participants from Canada and the U.S.A., which made for some meaningful time to learn and share from each other. Participants included those diagnosed with TTP (both recently and dating back years) and family members.
Our next session will be help on March 19, 2020. Again, call in details will be circulated about a week prior to the date via Community Annoucement to the Answering TTP Community.
On Thursday November 21, the Ohio State University TTP & aHUS offered a virtual and in-person support group.
Answering TTP Foundation had committed almost $2 million to research grants through 2021 thanks to our grass-roots fundraising campaigns like International TTP Day. The 2019 research competition attracted research proposals from North America and Europe. Proposals were peer reviewed by other TTP researchers and physicians. The winner was selected based on scientific merit.
The ISTH welcomes the public to comment on its draft recommendations for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP) via online survey only by October 21.
Answering TTP Foundation will submit feedback reviewed by a panel of patients and supporters. Clinicians, researchers, allied health professionals, policy makers, industry representatives, patients, caregivers, and other members of the public have been invited to contribute to this process.